

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
A1		Abbott NJ	Delivery of imaging agents into brain	Adv Drug Deliv Rev	1999	37(1-3)	253-77
A2		Abe Y	[Diagnostic utility of positron emission tomography for parkinsonism after chronic manganese exposure.]	Rinsho Shinkeigaku	1999	39(7)	693-9
A3		Agid Y	The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?	Adv Neurol	1990	53	83-100
A4		Agid Y	Pathophysiology of L-dopa-induced abnormal involuntary movements	Psychopharmacology Suppl	1985	(64)2	93-103
A5	27 (A2)	Antonini A	Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease	Brain	1997	120(Pt 12)	2187-95
A6		Antonini A	Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride	Mov Disord	1997	12(1)	33-8
A7	(A1)	Antonini A	Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease	Arch Neurol	1995	52(12)	1183-90
A8		Antonini A	[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors	Neurology	1994	44(7)	1325-9
A9	[A9]	Aquilonius SM	What has PET told us about Parkinson's disease?	Acta Neurol Scand Suppl	1991	136	37-9

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
A10		Aquilonius SM	Brain dopaminergic mechanisms in Parkinson's disease evaluated by positron emission tomography	Acta Neurol Scand Suppl	1989	126	55-9
A11		Aquilonius SM	In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography	Acta Neurol Scand	1987	76(4)	283-7
A12		Asahina M	[Muscarinic cholinergic receptor imaging of parkinsonian brain using 11C-NMPB and PET]	Nippon Rinsho	1997	55(1)	233-7
A13		Asahina M	Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET	Acta Neurol Scand	1995	91(6)	437-43
B1	56	Badawi RD	3D-Mode acquisition of clinical PET	Nucl Med Commun	1997	18	801-4
B2	57	Bailey DL	A convolution-subtraction scatter correction method for 3D PET	Phys Med Biol	1994	39	411-24
B3	14	Bailey DL	3D acquisition and reconstruction in positron emission tomography	Ann Nucl Med	1992	6(3)	123-30
B4	(A5) [ICP 1]	Barrio JR	Biological imaging and the molecular basis of dopaminergic diseases	Biochem Pharmacol	1997	54(3)	341-8
B5		Barrio JR	Radiofluorinated L-m-tyrosine; new in-vivo probes for central dopamine biochemistry	J Cereb Blood Flow Metab	1996	16(4)	667-78
B6	(B3) [ICP 2]	Barrio JR	6-[18F]fluoro-L-dopa probes dopamine turnover rates in central dopaminergic structures	J Neurosci Res	1990	27(4)	487-93
B7	21	Bernheimer H	Brain dopamine and the syndromes of Parkinson and Huntington	J Neurol Sci	1973	20	415-55

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
B8		Bhatt MH	Positron emission tomography in progressive supranuclear palsy	Arch Neurol	1991	48(4)	389-91
B9		Blesa R	[PET and SPECT in Parkinson's disease].	Rev Neurol	1997	25 Suppl 2	S147-50
B10	(A6)	Boecker H	Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]fluorodopa	Acta Neurol Scand	1996	93(6)	387-92
B11		Bohnen NI	(+)-alpha-[11C]Dihydrotetabenazine PET imaging in familial paroxysmal dystonic choreoathetosis	Neurology	1999	52(5)	1067-9
B12		Booij J	Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease	Eur J Nucl Med	1997	24(1)	68-71
B13	(A7) [ICP 3]	Boytes BE	Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects	Life Sci	1986	39(23)	2243-52
B14		Brannan T	In vivo studies of striatal dopamine release and metabolism following administration of L-dopa	Adv Neurol	1990	53	75-81
B15		Brashears A	PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP)	Mov Disord	1999	14(1)	132-7
B16	67	Brooks DJ	The early diagnosis of Parkinson's disease	Ann Neurol	1998	44 (3sup1)	S10-8
B17	[B17]	Brooks DJ	Positron emission tomography studies in movement disorders	Neurosurg Clin North Am	1998	9(2)	263-81
B18		Brooks DJ	Motor disturbance and brain functional	Eur Neurol	1997	38	26-32

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			imaging in Parkinson's disease			Suppl 2	
B19	24	Brooks DJ	Advances in imaging Parkinson's disease	Curr Opin Neurol	1997	10(4)	327-31
B20		Brooks DJ	PET and SPECT studies in Parkinson's disease	Baillieres Clin Neurol	1997	6(1)	69-87
B21	[B21]	Brooks DJ	Functional imaging in relation to parkinsonian syndromes	J Neurol Sci	1993	115(1)	1-17
B22	[ICP 4]	Brooks DJ	PET studies on the early and differential diagnosis of Parkinson's disease	Neurology	1993	36(1)	27-31
B23	[ICP 5]	Brooks DJ	Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study	Neurology	1992	42(8)	1554-60
B24		Brooks DJ	Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography	Ann Neurol	1992	31(2)	184-92
B25	[ICP 6]	Brooks DJ	Detection of preclinical Parkinson's disease with PET	Geriatrics	1991	46 suppl 1	25-30
B26	66	Brooks DJ	Presynaptic and postsynaptic striatal dopaminergic function in enuroacanthocytosis: a positron emission tomographic study	Ann Neurol	1991	30(2)	166-71
B27	[ICP 7]	Brooks DJ	The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease,	Brain	1990	113 (pt 5)	1539-52

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			studied with PET				
B28	[ICP 8]	Brooks DJ	Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy	Ann Neurol	1990	28(4)	547-55
B29		Broussolle E	The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease	J Neurol Sci	1999	166(2)	141-51
B30		Broussolle E	Relief of akinesia by apomorphine and cerebral metabolic changes in Parkinson's disease	Mov Disord	1993	8(4)	459-62
B31	55	Brown WD	FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa	Neurology	1999	53(6)	1212-8
B32	45	Brown WD	Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa treatment	J Nucl Med	1998	39(11)	1884-91
B33		Brownell AL	Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease	Nat Med	1998	4(11)	1308-12
B34	29	Brucke T	Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy	J Neural Transm Suppl	1997	50	9-24
B35		Brucke T	Dopamine receptor classification, neuroanatomical distribution and in vivo imaging	Wien Klin Wochenschr	1991	103(21)	639-46
B36		Brust P	Upregulation of the aromatic amino acid	Neurobiol Dis	1999	6(2)	131-9

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			decarboxylase under neonatal asphyxia				
B37		Brust P	Simulataneous measurment of [18F]FDOPA metabolism and cerebral blood flow in newborn piglets	Int J Dev Neurosci	1998	16(5)	353-64
B38		Burn DJ	Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study	Neurology	1993	43 (3 Pt 1)	552-6
B39		Burn DJ	Parkinson's disease in twins studied with 18F-dopa and positron emission tomography	Neurology	1992	42(10)	1894-900
B40		Burns RS	Subclinical damage to the nigrostriatal dopamine system by MPTP as a model of preclinical Parkinson's disease: a review	Acta Neurol Scand Suppl	1991	136	29-36
C1		Calne DB	Contributions of positron emission tomography to elucidating the pathogenesis of idiopathic parkinsonism and dopa responsive dystonia	J Neural Transm Suppl	1997	50	47-52
C2		Calne DB	PET imaging in Parkinsonism	Adv Neurol	1993	60	484-7
C3		Calne DB	Dopamine agonists in Parkinson's disease	Can J Neurol Sci	1984	11 1 Suppl	221-4
C4		Caparros-Lefebvre D	PET study and neuropsychological assessment of a long-lasting post-encephalitic parkinsonism	J Neural Transm	1998	105(4-5)	489-95
C5		Caraceni TA	Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment	J Neural Transm Suppl	1986	22	189-99
C6		Cardoso F	Peripherally induced tremor and parkinsonism	Arch Neurol (BIOA1995981 90778)			
C7		Carlsson A	Possible mechanisms underlying the special	Acta Neurol	1991	136	16-8

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			vulnerability of dopaminergic neurons	Scand Suppl			
C8		Carlsson A	Are “on-off” effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?	J Neural Transm Suppl	1983	19	153-61
C9		Chan GL	Routes of administration and effect of carbidopa pretreatment on 6-[18F]fluoro-L-dopa/PET scans in non-human primates	Life Sci	1995	56(21)	1759-66
C10		Chan GL	Routine determination of [18F]-L-6-fluorodopa and its metabolites in blood plasma is essential for accurate positron emission tomography studies	Life Sci	1992	50(4)	309-18
C11	(A10)	Chan GL	Plasma L-[18F]6-fluorodopa input function: a simplified method	J Cereb blood Flow Metab	1992	12(5)	881-4
C12		Chang MH	Resting tremor only: A variant of Parkinson’s disease or of essential tremor	J Neurol Sci (BIOA1995983 63454)			
C13	65	Cherry SR	Correction and characterization of scattered events in three-dimensional PET using scanners with retractable septa	J Nucl Med	1993	34	671-8
C14	22	Cherry SR	3D PET using a conventional multislice tomograph without septa	J Comput Assist Tomogr	1991	15(4)	655-68
C15	[C15]	Cleghorn JM	Apomorphine effects on brain metabolism in enuroleptic-naïve schizophrenic patients	Psychiatry Res	1991	40(2)	135-53
C16	61	Colosimo C	Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from parkinson’s disease	Arch Neurol	1995	52	294-98
C17		Cooper JM	L-dihydroxyphenylalanine and complex I deficiency in Parkinson’s disease brain.	Mov Disord	1995	10(3)	295-7

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
C18		Cordes M	Age-dependent decline of nigrostriatal dopaminergic function: a positron emission tomographic study of grandparents and their grandchildren	Ann Neurol	1994	36(4)	667-70
C19		Cordes M	Examination of the presynaptic dopaminergic system using positron emission tomography in a family with autosomal dominant parkinsonism and dementia due to pallido-ponto-nigral degeneration	Radio Diagn	1993	34(3)	141-5
C20		Cordes M	Parametric imaging of the rate constant Ki using [18Fluoro]-L-dopa positron emission tomography in progressive supranuclear palsy	Neuroradiology	1993	35(6)	404-9
C21		Cordes M	[L-18F-dopa-PET in Parkinson-plus syndromes for the detection of a disordered presynaptic dopaminergic function]	Nuklearmedizin	1992	31(2)	43-7
C22		Creveling CR	The effect of ring-fluorination on the rate of O-methylation of dihydroxyphenylalanine (DOPA) by catechol-O-methyltransferase: significance in the development of 18F-PET scanning agents	Biochem Biophys Res Commun	1985	130(3)	1123-31
C23		Cumming P	Pharmacokinetics of radiotracers in human plasma during positron emission tomography	Synapse	1999	34(2)	124-34
C24		Cumming P	Cocaine withdrawal and the cerebral influx of [18F]fluoro-L-DOPA	Neuropharmacology	1999	20(4)	395-98
C25		Cumming P	Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms	Synapse	1998	29(1)	37-61
C26	44	Cumming P	Controversies arising from recent FDOPA	J Nucl Med	1997	38(8)	1267-71

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			articles				
C27		Cumming P	Metabolism and blood-brain clearance of L-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-L-DOPA in the rat	Biochem Pharmacol	1995	50(7)	943-6
C28		Cumming P	A kinetic analysis of 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism in the rat	J Neurochem	1994	63(5)	1675-82
C29	(A13) [ICP 11]	Cumming P	Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans	J Cereb Blood Flow Metab	1993	13(4)	668-75
D1		Da Prada M	The pharmacology of Parkinson's disease: basic aspects and recent advances	Experientia	1984	40(11)	1165-72
D2		Danielsen EH	Cerebral 6-[(18)F]fluoro-L-DOPA (FDOPA) metabolism in pig studied by positron emission tomography	Synapse	1999	33(4)	247-58
D3		Darke AC	Critical opening pressure and reactivity of tail vessels in conscious hypertensive rats	Can J Physiol Pharmacol	1976	54(3)	314-21
D4	(A19)	Deep P	Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine	Synapse	1999	34(4)	313-18
D5		Deep P	On the accuracy of an [18F]FDOPA compartmental model: evidence for vesicular storage of [18F]fluorodopamine in vivo	J Neurosci Methods	1997	76(2)	157-65
D6		Defer GL	Rest tremor and extrapyramidal symptoms after midbrain haemorrhage: clinical and 18F-dopa PET evaluation	J Neurol Neurosurg Psychiatry	1994	57(8)	987-9
D7		Defer GL	Long-term outcome of unilaterally	Brain			

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			transplanted parkinsonian patients: I. Clinical approach	(BIOA1996987 79511)			
D8		Dejesus OT	Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: Comparison with 6-fluorodopa	J Nucl Med (BIOA1997995 23020)			
D9		Dewey RB	Long-term follow-up of levodopa responsiveness in generalized dystonia	Arch Neurol	1998	55(10)	1320-3
D10		Dewey SL	Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects	Proc Natl Acad Sci USA	1993	90(24)	11816-20
D11		Dewey SL	Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels	Synapse	1993	13(4)	350-6
D12		Dewey SL	Positron emission tomography (PET) studies of dopaminergic/cholinergic interactions in the baboon brain	Synapse	1990	6(4)	321-7
D13		Dhawan V	Double-blind controlled trial of human embryonic dopaminergic tissue transplants in advanced Parkinson's disease: Fluorodopa PET imaging	Neurology	1999	52 (6 Suppl 2)	A405-6
D14	(A21)	Dhawan V	Combined FDOPA and 3OMFD PET studies in Parkinson's disease	J Nucl Med	1996	37(2)	209-16
D15	(A20)	Dhawan V	Bladder wall radiation dose in humans from fluorine-18-FDOPA	J Nucl Med	1996	37(11)	1850-2
D16	9	Donnan GA	Evidence for plasticity of the dopaminergic system in parkinsonism	Mol Neurobiol	1991	5(2-4)	421-33
D17		Doudet DJ	6-[18F]Fluoro-L-DOPA PET studies of the	Synapse	1998	29(3)	225-32

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			turnover of dopamine in MPTP-induced parkinsonism in monkeys				
D18		Doudet DJ	Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys	Neuropharmacology	1997	36(3)	363-71
D19		Doudet DJ	6-18F-L-DOPA imaging of the dopamine neostriatal system in normal and clinically normal MPTP-treated rhesus monkeys	Exp Brain Res	1989	78	69-80
D20		Dunn BB	A single column, rapid quality control procedure for 6-[18F]fluoro-L-dopa and 6-[18F]fluorodopamine PET imaging agents	Int J Rad Appl Instrum	1991	18(2)	209-13
E1		Edling C	Do organic solvents induce changes in the dopaminergic system? Positron emission tomography studies of occupationally exposed subjects.	Int Arch Occup Environ Health	1997	70(3)	180-6
E2		Edling C	Positron emission tomography studies of healthy volunteers—no effects on the dopamine terminals an synthesis after short-term exposure to toluene	Hum Exp Toxicol	1997	16(93)	171-6
E3	(A26)	Eidelberg D	Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography	Neurology	1995	45(11)	1995-2004
E4	(A25) [ICP 14]	Eidelberg D	Striatal 18f-dopa uptake: absence of an aging effect	J Cereb Blood Flow Metab	1993	13(5)	881-8
E5		Eidelberg D	Positron emission tomographic findings in Filipino X-linked dystonia-parkinsonism	Ann Neurol	1993	34(92)	185-91

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
E6	12	Eidelberg D	Positron emission tomography studies in parkinsonism	Neurol Clin	1992	10(2)	421-33
E7	(A24)	Eidelberg D	The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F] fluorodopa positron emission tomographic studies	Mov Disord	1990	5(3)	203-13
E8		Ekesbo A	Dopamine autoreceptor function is lost in advanced Parkinson's disease	Neurology	1999	52(1)	120-5
E9		Ernst M	High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder	Am J Psychiatry	1999	156(8)	1209-15
E10		Ernst M	High presynaptic dopaminergic activity in children with Tourette's disorder	J Am Acad Child Adolesc Psychiatry	1999	38(1)	86-94
E11		Ernst M	DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [F-18]fluorodopa positron emission tomographic study	J Neurosci	1998	18(15)	5901-7
E12		Ernst M	Presynaptic dopaminergic deficits in Lesch-Nyhan disease	N Eng J Med	1996	334(24)	1568-72
F1		Fahn S	Controversies in the therapy of Parkinson's disease	Adv Neurol	1996	69	477-86
F2		Fallen EL	Recovery rates of regional sympathetic reinnervation and myocardial blood flow after acute myocardial infarction	Am Heart J	1999	137(5)	863-9
F3		Farde L	Brain imaging of schizophrenia – The dopamine hypothesis	Psiquiatr Biol	1998	6(2)	87-91

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
F4		Farde L	The advantage of using positron emission tomography in drug research	Trends Neurosci	1996	19(6)	211-14
F5	37	Fernley JM	Ageing and Parkinson's disease: substantia nigra regional selectivity	Brain	1991	114	2283-301
F6		Firnau G	New 18F tracers for the investigation of brain functions	Acta Radiol Suppl	1990	374	37-41
F7		Fischman AJ	Rapid detection of Parkinson's disease by SPECT with altropine: a selective ligand for dopamine transporters	Synapse	1998	29(2)	128-41
F8		Fowler JS	Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327	Neurology	1993	43(10)	1984-92
F9		Freed CR	Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease	N Engl J Med	1992	327(22)	1549-55
F10		Freed CR	Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year	Arch Neurol	1990	47(5)	505-12
F11		Freeman TB	Bilateral fetal nigral transplantation into the postcommisural putamen Parkinson's disease	Ann Neurol	1995	38(3)	379-88
F12		Frey KA	Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging	Ann Neurol	1996	40(6)	873-84
F13		Friedman J	Recent research advances in Parkinson's disease: Part I	R I Med J	1986	69(7)	319-22
F14	23	Friston KJ	Comparing functional (PET) images: the assessment of significant change	J Cereb Blood Flow Metab	1991	11	690-9
F15		Frost JJ	Positron emission tomographic imaging of	Ann Neurol	1993	34(3)	423-31

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			the dopamine transporter with ¹¹ C-WIN 35,428 reveals marked declines in mild Parkinson's disease				
F16		Fujii R	[Fluorine-18 labeled 6-fluoro-L-dopa: systematization and evaluation of its usefulness.]	Kaku Igaku	1997	34(11)	1055-61
G1	[G1]	Garnett ES	Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography	Can J Neurol Sci	1984	11 (1 Suppl)	174-9
G2	3	Gelb DJ	Diagnostic criteria for parkinson disease	Arch Neurol	1999	56	33-9
G3		Gerfen CR	Molecular neuroanatomic mechanisms of Parkinson's disease: a proposed therapeutic approach	Neurol Clin	1992	10(2)	435-49
G4	1	Gibb WRG	Accuracy in the clinical diagnosis of parkinsonian syndromes	Postgrad Med J	1988	64	345-51
G5	[G5]	Gjedde A	Striatal L-dopa decarboxylase activity in Parkinson's disease <i>in vivo</i> : implications for the regulation of dopamine synthesis	J Neurochem	1993	61(4)	1538-41
G6	55	Gjedde A	Dopa decarboxylase activity of the living human brain	Proc Natl Acad Sci USA	1991	88(7)	2721-5
G7		Goldman S	[Positron emission tomography in akinetic rigidity syndrome]	Rev Med Brux	1995	16(6)	399-403
G8		Goldstein DS	Sympathetic cardioneuropathy in dysautonomias	New Engl J Med	1997	336(10)	696-702
G9		Goldstein DS	Metabolic fate of the sympathoneuronal imaging agent 6-[¹⁸ f]fluorodopamine in humans	Clin Exp Hypertens	1997	19(1-2)	155-51
G10		Goldstein DS	6-(F-18)fluorodopamine pharmacokinetics	J Nucl Med	1994	35(6)	964-73

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			and dosimetry in humans				
G11		Goldstein DS	Chemical mediators of autonomic nervous system activity	Curr Opin Neurol Neurosurg	1993	6(4)	524-6
G12		Gunther I	Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltranseferase inhibitors on metabolism of [NCA] 6-18F]flouro-L-dopa in rhesus monkey	Nucl Med Biol	1995	22(7)	921-7
G13		Guttman M	Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa	Mov Disord	1993	8(3)	298-304
G14	[G14]	Guttman M	Dopamine receptors in Parkinson's disease	Neurol Clin	1992	10(2)	377-86
G15		Guttman M	Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys	Synapse	1988	2(5)	469-73
G16		Guttman M	L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum	J Neural Transm	1985	64(2)	93-103
H1	70	Hachinski V	Levodopa Toxicity	Arch Neurol	2000	57	410
H2		Hagell P	Sequential bilateral transplantation in Parkinson's disease: Effects of the second graft	Brain	1999	122(6)	1121-32
H3		Hagglund J	Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone	Acta Neurol Scand	1987	75(2)	87-94
H4		Hagglund J	Regional kinetics of [11C]methylspiperone in the brain studied by positron emission	Adv Neurol	1987	45	99-101

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			tomography in patients with Parkinson's disease				
H5		Harder S	Levodopa PK-PD-analysis in relation to (18F)-Dopa-PET in patients with Parkinsons disease	Clin Pharmacol Ther	1999	65(2)	169
H6	63	Hardie RJ	Measuring the rate of progression and estimating the preclinical period Parkinson's disease with [18F] dopa PET	J Neurol Neurosurg Psychiatry	1999	66(2)	256
H7		Hartvig P	Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography	J Neural Transm	1997	104(4-5)	329-39
H8		Hartvig P	Brain Kinetics of L-beta-carbon-11 dopa in humans studied by positron emission tomography	J Neural Transm	1991	86(1)	25-42
H9		Hassan MN	Dopamine receptors in Parkinson's disease	Prog Neuropsychopharmacol Biol Psychiatry	1988	12(2-3)	173-82
H10		Hauser RA	Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease	Arch Neurol	1999	56(2)	179-87
H11		Heiss WD	F-Dopa as an amino acid tracer to detect brain tumors	J Nucl Med	1996	37(7)	1180-2
H12		Hietala J	Depressive symptoms and presynaptic dopamine function in neuroleptinaive schizophrenia	Schizophr Res	1999	35(1)	41-50
H13		Hietala J	Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients	Lancet	1995	346 (8983)	1130-1

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
H14		Hoegerle S	Imaging of a metastatic gastrointestinal carcinoid by F-18-DOPA positron emission tomography	Nuklearmedizin	1999	38(4)	127-30
H15	54	Hoehn MM	Parkinsonism: onset, progression, and mortality	Neurology	1967	17	427-42
H16		Hoffer BJ	Eighteen-month course to two patients with grafts of fetal dopamine neurons for severe Parkinson's disease	Exp Neurol	1992	118(3)	243-52
H17	(A30)	Hoffman JM	The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography	J Nucl Med	1992	33(8)	1472-7
H18		Holthoff VA	Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits	Ann Neurol	1994	36(2)	176-82
H19		Holthoff VA	Functional effects of striatal dysfunction in Parkinson disease	Arch Neurol (BIOA1997994 59959)			
H20		Hornykiewicz O	Brain monoamines and parkinsonism	Natl Inst Drug Abuse Res Monogr Ser	1975	3	13-21
H21		Horstink MW	L-dopa in Parkinson's disease	Neurology	1991	41(10)	1709
H22	(A31)	Hoshi H	6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods	J Cereb Blood Flow Metab	1993	13(1)	57-69
H23		Huang SC	Modelling approach for separating blood time-activity curves in positron emission tomographic studies	Phys Med Biol	1991	36(6)	749-61
H24	(B1)	Huang SC	Kinetics and modeling of L-6-[18f]fluoro-	J Cereb Blood	1991	11(6)	898-913

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
	[ICP 15]		dopa in human positron emission tomographic studies	Flow Metab			
H25	16	Hughes AJ	The clinical features of Parkinson's disease in 100 histologically proven cases	Adv Neurol	1993	60	595-9
H26	35/62	Hughes AJ	Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases	J Neurol Neurosurg Psychology	1992	55	181-4
H27	34	Hughes AJ	What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study	Neurology	1992	42	1142-6
I1	[I1]	Iacoboni M	Emission tomography contribution to clinical neurology	Clin Neurophysiol	1999	110(1)	2-23
I2		Ichise M	Physiologic modeling of PET data: quantitative conflict and challenge	J Nucl Med	1997	38(8)	1266-7
I3		Ilgin N	Functional imaging of neurotransmitter systems in movement disorders	Q J Nucl med	1998	42(3)	179-92
I4		Indo T	[Striatal dopamine availability in Parkinson's disease—with reference to the wearing-off phenomenon]	Rinsho shinkeigaku	1984	24(10)	1008-16
I5		Inoue Y	Atlas of dopamine receptor images (PET) of the human brain	J Comput Assist Tomogr	1985	9(1)	129-40
I6	(B4) [ICP 16]	Ishikawa T	Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease	J Nucl Med	1996	37(2)	216-22
I7	(B3)	Ishikawa T	Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET	J Nucl med	1996	37(11)	1760-5
I8	(B2)	Ishikawa T	Fluorodopa positron emission tomography	J Cereb Blood	1996	1695)	854-63

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis	Flow Metab			
I9		Ishiwata K	Synthesis and evaluation of an 18F-labeled dopa prodrug as a PET tracer for studying brain dopamine metabolism	Nucl Med Biol	1996	23(3)	295-301
I10		Ishiwata K	Selective 2-[18F]fluorodopa uptake for melanogenesis in murine metastatic melanomas	J Nucl Med	1991	32(1)	95-101
I11	58	Ito K	Statistical parametric mapping with 18F-dopa PET show bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease	J Neurol Neurosurg Psychiatry	1999	66(6)	754-8
I12		Itoh M	[In vivo visualization of neurotransmitter function in the human brain by PET]	No To hattatsu	1995	27(2)	146-52
I13	(B7)	Itoh M	Assessment of dopamine metabolism in brain of patients with dementia by means of 18F-fluorodopa and PET	Ann Nucl Med	1994	8(4)	245-51
J1	71	Jankovic J	The evolution of diagnosis in early Parkinson disease	Arch Neurol	2000	57	369-72
K1	2	Kaakkola S	General properties and clinical possibilities of new selective inhibitor of catechol O-methyltransferase	Gen Pharmacol	1994	25(5)	813-24
K2		Kaneko S	Enzymatic synthesis of no-carrier-added 6-[18F]fluoro-L-dopa with beta-tyrosinase	Appl Radiat Isot	1999	50(6)	1025-32
K3		Kapfhammer HP	[Dopamine agonists in the therapy of parkinson syndrome]	Nervenarzt	1985	56(2)	69-81
K4		Kapur S	Role of the dopaminergic system in	Biol Psychiatry	1992	32(1)	1-17

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			depression				
K5	30	Karbe H	Positron emission tomography in degenerative disorders of the dopaminergic system	J Neural Transm Park dis Dement Sect	1992	4(2)	121-30
K6		Kempster PA	Dietary factors in the management of Parkinson's disease	Nutr Rev	1994	52 (2 Pt 1)	51-8
K7		Kilbourn MR	In vivo radiotracers for vesicular neurotransmitter transporters	Nucl Med Biol	1997	24(7)	615-9
K8		Kim JW	Manganese induced parkinsonism: a case report	J Korean Med Sci	1998	13(4)	437-9
K9		Kim Y	Positron emission tomography (PET) in differentiating manganism from idiopathic parkinsonism	J Occupational Health	1999	41(2)	91-4
K10		Kim Y	Idiopathic parkinsonism with superimposed manganese exposure: utility of positron emission tomography	Neurotoxicology	1999	20(2-3)	249-52
K11	7	Kish SJ	Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies?	Ann Neurol	1995	38(2)	260-4
K12	33	Kish SJ	Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease	N Engl J Med	1988	318	876-80
K13		Kishore A	Presynaptic nigrostriatal function in genetically tested asymptomatic relatives from the pallido-ponto-nigral degeneration family	Neurology	1996	47(6)	1588-90
K14		Koide T	Three Cases of clinically diagnosed	Rinsho	1995	35(11)	1184-90

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			corticobasal degeneration –neuroimaging studies with MRI, SPECT, and PET	Shinkeigaku			
K15	11	Koller WC	When does Parkinson's disease begin?	Neurology	1992	42 (4sup4)	27-31
K16		Kopin IJ	In-vivo quantitative imaging of catecholaminergic nerve terminals in brain and peripheral organs using positron emission tomography (PET)	J Neural Transm Suppl	1990	32	19-27
K17		Kordower JH	Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease	Mov Disord	1998	13(3)	383-93
K18		Kordower JH	Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with parkinson's disease	N Engl J Med	1995	332(17)	1118-24
K19		Kubota R	Active melanogenesis in non-S phase melanocytes in B16 melanomas in vivo investigated by double-tracer microautoradiography with ¹⁸ F-fluorodopa and ³ H-thymidine	Br J Cancer	1992	66(4)	614-8
K20		Kung HF	Overview of radiopharmaceuticals for diagnosis of central nervous disorders	Crit Rev Clin Lab Sci	1991	28(4)	269-86
K21		Kuno S	Dilemma in the treatment of Parkinson's disease with L-dopa	Eur Neurol	1994	34 Suppl 3	17-9
K22		Kuwabara H	Blood-to-brain transport of large neutral amino acids studied with (¹⁸ F)fluoro-DOPA ((¹⁸ F)FDOPA and PET	J Nucl	1998	39 (5 Suppl)	43P
K23	(B11)	Kuwabara H	Regional striatal DOPA transport and	J Nucl Med	1995	36(7)	1226-31

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			decarboxylase activity in Parkinson's disease				
K24	(B10) [ICP 17]	Kuwabara H	Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects	J Cereb Blood Flow Metab	1993	13(1)	43-56
K25		Kuzuhara S	[Recent therapeutic advances in geriatric neurology]	Nippon Ronen Igakkai Zasshi	1992	29(7-8)	531-9
L1	[ICP 18]	Laihinan A	[18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462)	Neurology	1992	42(1)	199-203
L2		Laihinan AO	PET studies on brain monoamine transporters with carbon-11-beta-CIT in Parkinson;s disease	J Nucl Med	1995	36(7)	1263-7
L3		Laihinan AO	PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756	J Nucl Med	1994	35(12)	1916-20
L4	39	Lang AE	Parkinson's disease (First of Two Parts)	N Engl J Med	1998	339(15)	1044-53
L5	40	Lang AE	Parkinson's disease (Second of Two Parts)	N Engl J Med	1998	339(16)	1130-43
L6		Lang AE	Hemiatrophy, juvenile-onset exertional alternating leg paraesisis, hypotonic and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome	Mov Disord	1995	1994)	489-95
L7	53	Lang AE	Dopa-responsive parkinsonism with normal 6[18F]-fluorodopa positron emission tomography scans	Ann Neurol	1990	28(4)	592-3
L8		Lee CS	Heterogeneous severity of lesions in the striatum of patients with Parkinson's disease:	Neurology	1998	50 (4 suppl)	A391-2

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			In vivo PET studies using dihydrotetrabenazine, methyphenidate and F-DOPA			4)	
L9	[ICP 21]	Leender KL	Pathophysiology of movement disorders studied using PET	J Neural Transm Suppl	1997	50	39-46
L10		Leenders KL	The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease	Arch Neurol	1990	47(12)	1290-8
L11		Leenders KL	Parkinson's disease and PET tracer studies	J Neural Transm Suppl	1988	27	219-25
L12	[ICP 20]	Leenders KL	Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography	J Neurol Neurosurg Psychiatry	1986	49(8)	853-60
L13	(B12)	Leger G	Effect of catechol-O-methyltranseferase inhibition on brain uptake of [18F]fluorodopa: implications for compartmental modelling and clinical usefulness	Synapse	1998	30(4)	351-64
L14	[L14]	Lenzi GL	PET studies of the dopaminergic system	J Nucl Med Allied Sci	1990	34(1)	1-9
L15		Levivier M	Intracerebral transplantation of fetal ventral mesencephalon for patient with advanced Parkinson's disease. Methodology and 6-month to 1-year follow-up in 3 patients	Stereoract Funct Neursurg	1997	69(1-4 Pt 2)	99-111
L16	(B13)	Lin KP	Automated image registration for FDOPA PET studies	Phys Med Biol	1996	41(12)	2775-88
L17		Lindvall O	Grafts of fetal dopamine neurons survive and	Science	1990	247	574-7

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			improve motor function in Parkinson's disease			(4942)	
L18		Lindvall O	Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease	Ann Neurol (BIOA1994971 76797)			
L19	42	Louis ED	Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease	Neurology	1997	48	376-80
L20	(B14)	Luxen A	Production of 6-[18F]fluoro-L-dopa and its metabolism in vivo—a critical review	Int J Rad Appl Instrum B	1992	19(2)	149-58
L21		Luxen A	Remote, semiautomated production of 6-[18F]fluoro-L-dopa for human studies with PET	Int J Rad Appl Instrum	1990	41(3)	275-81
M1		Marie RM	Quantification of dopamine transporter density in monkeys by dynamic PET imaging of multiple injections of 11C-CFT	Synapse	1996	24(3)	262-72
M2		Marie RM	PET imaging of neocortical monoaminergic terminals in Parkinson's disease	J Neural Transm Park Dis Dement Sect	1995	9(1)	55-71
M3	41	Mark MH	Levodopa-nonresponsive Lewy body parkinsonism: Clinicopathologic study of two cases	Neurology	1992	42	1323-7
M4		Martin WR	Assessment of fetal tissue transplantation in Parkinson's disease: does PET play a role?	Neurology	1994	44(10)	1777-80
M5	[ICP 22]	Martin WR	Nigrostriatal function in humans studied with positron emission tomography	Ann Neurol	1989	26	535-42

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
M6		Martin WR	Parkinson's disease: positron emission tomographic studies	Semin Neurol	1989	9(4)	345-50
M7		Maziere B	PET radioligands for dopamine receptors and re-uptake sites: chemistry and biochemistry	Int J Rad Appl Insturm	1992	19(4)	497-512
M8	(B15)	Meguro K	Striatal dopamine metabolism correlated with frontotemporal glucose utilization in Alzheimer's disease: a double-tracer PET study	Neurology	1997	55(8)	2148-55
M9	(B16)	Mejia AA	Absorbed dose estimates in positron emission tomography studies based on the administration of 18f-labeled radiopharmaceuticals	J Radiat Res	1991	32(3)	243-61
M10		Melamed E	Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease	Adv Neurol	1990	53	61-6
M11		Melamed E	Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease	Mt Sinai j Med	1988	55(1)	35-42
M12		Melega WP	Ethological and 6-[18F]fluoro-L-DOPA-PET profiles of long-term vulnerability to chronic emphetamine	Behav Brain Res	1997	84(1-2)	259-68
M13		Melega WP	Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the rhesus monkey	Brain Res	1997	766(1-2)	113-20
M14		Melega WP	Longitudinal behavioral and 6-[18F]fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys	Exp Neurol	1996	141(2)	318-29
M15		Melega WP	6-[18F]fluoro-L-DOPA-PET Studies show	Synapse	1996	22(1)	63-9

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			partial reversibility of long-term effects of chronic amphetamine in monkeys				
M16	(B19)	Melega WP	L-6-[18F]fluoro-dopa metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography	J Cereb Blood Flow Metab	1991	11(6)	890-7
M17		Melega WP	6-[18F]fluoro-L-DOPA metabolism in MPTP-treated monkeys: assessment of tracer methodologies for positron emission tomography	Brain Res	1990	543	271-6
M18	(B18) [ICP 23]	Melega WP	The effects of carbidopa on the metabolism of 6-[18F]fluoro-L-dopa in rats, monkeys and humans	Life Sci	1990	47(2)	149-57
M19		Melega WP	Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats	Biochem Pharmacol	1990	39(12)	1843-60
M20		Menza MA	Personality correlates of [18F]dopa striatal uptake: results of positron emission tomography in Parkinson's disease	J Neuropsychiatry Clin Neurosci	1995	7(2)	176-9
M21		Mercuri NB	Physiology and pharmacology of dopamine D2-receptors: their implications in dopamine-substitute therapy for Parkinson's disease	Neurology	1989	39(8)	1106-8
M22		Miller GW	Immunochemical analysis of dopamine transporter protein in Parkinson's disease	Ann Neurol	1997	41(4)	530-9
M23		Minami T	Different patterns of [18F]dopa uptake in siblings with hereditary dentato-rubro-pallido-luysian atrophy	Brain Dev	1994	16(4)	335-8
M24		Momose T	[Striatal dopamine D2 receptor in Parkinson	Nippon Rinsho	1997	55(1)	227-32

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			disease and its related disorders assessed by C-11 NMSP and PET]				
M25		Morris ED	Quantification of dopamine transporter density in monkeys by dynamic PET imaging of multiple injections of 11C-CFT	Synapse	1996	24(3)	262-72
M26	60	Morrish PK	Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET	J Neurol Neurosurg Psychiatry	1998	64(3)	314-9
M27		Morrish PK	Parkinson's disease is not a long-latency illness	Mov Disord	1997	12(6)	849-54
M28	51 [ICP 26]	Morrish PK	An [18F]dopa PET and clinical study of the rate of progression in Parkinson's disease	Brain	1996	119	585-91
M29	52	Morrish PK	Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease	Brain	1996	119	2097-2103
M30	15	Morrish PK	The rate of progression of Parkinson's disease. A longitudinal [18F]DOPA PET study	Adv Neurol	1996	69	427-31
M31	[ICP 27]	Morrish PK	Clinical and [18F]dopa PET findings in early Parkinson's disease	J Neurol Neurosurg Psychiatry	1995	59(6)	597-600
M32	27	Muenter MD	Hereditary form of parkinsonism—dementia	Ann Neurol	1998	43(6)	768-81
M33		Muller T	2-[123I]-iodoisuride SPET visualizes dopaminergic loss in de-novo parkinsonian patients: is it a marker of striatal pre-synaptic degeneration?	Nucl Med Commun	1997	18(12)	1115-21
M34		Murali D	[18F]fluoro-beta-fluromethylene-m-tyrosine analogs, potential PET agents for presynaptic	Int J Rad Appl Instrum	1992	43(8)	969-77

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			dopamine terminals: synthesis and spectroscopic characterization				
N1		Nagasaki H	[PET study using 6-[18F]fluorodopa metabolism in early and late onset of Parkinson's disease studied by positron emission tomography]	Nippon Rinsho	1997	55(1)	213-7
N2		Nagasaki H	PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration	J Neurol Sci	1996	139(2)	210-7
N3	18	Nagasaki H	Brain 6-[18F]fluorodopa metabolism in early and late onset of Parkinson's disease studied by positron emission tomography	J Neurol Sci	1996	144(1-2)	70-6
N4	20	Nagasaki H	6-[18F]fluorodopa metabolism in patients with hemiparkinsonism studied by positron emission tomography	J Neurol Sci	1993	115(2)	136-43
N5	[ICP 28]	Nahmias C	Striatal dopamine distribution in parkinsonian patients during life	J Neurol Sci	1985	69	223-30
N6		Naumann M	[123I]beta-CIT single-photon emission tomography in DOPA-responsive dystonia	Mov Diord	1997	12(3)	448-51
N7		Nygaard TG	Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia	Ann Neurol	1992	32(5)	603-8
O1		Okada A	PET scan study on the dopaminergic system in a Japanese patient with hereditary progressive dystonia (Segawa's disease). Case report	Adv Neurol	1993	60	591-4
O2		Opacka-Juffry	L-dihydroxyphenylalanine and its	Mov Disord	1995	10(3)	241-9

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
		J	decarboxylase: new ideas on their neuroregulatory roles				
O3		Oreland L	Monoamine oxidase, dopamine and Parkinson's disease	Acta Neurol Scand Suppl	1991	136	60-5
O4		Orihara H	Three-Dimensional positron emission tomography imaging system and its application for medical use	Nippon Rinsho	1997	55(8)	2148-55
O5		Osman L	The effect of peripheral catechol-O-methyl transferase inhibitor OR-611 (entacapone) on the metabolism of 6-(18F)fluoro-L-dopa	J Label Compd Radiopharm	1994	35	543-45
O6	25	Otsuka M	Differentiating between multiple system atrophy and Parkinson's disease positron emission tomography with 18F-dopa and 18F-FDG	Ann Nucl Med	1997	11(3)	251-7
O7	19	Otsuka M	Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms	J Neurol Sci	1996	136(1-2)	169-73
O8		Otsuka M	Nigrofrontal dopaminergic function as assessed by 18F-dopa PET	Nucl Med Commun	1995	16(12)	1021-5
O9		Otsuka M	Cerebral glucose metabolism and striatal 18F-dopa uptake by PET in cases of chorea with or without dementia	J Neurol Sci	1993	115(2)	153-7
O10		Otsuka M	Increased striatal 18F-dopa uptake and normal glucose metabolism in idiopathic dystonia syndrome	J Neurol Sci	1992	111(2)	195-9
O11		Otsuka M	Striatal blood flow, glucose metabolism and 18f-dopa uptake: difference in Parkinson's	J Neurol Neurosurg	1991	54(10)	898-904

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			disease and atypical Parkinsonism	Psychiatry			
O12		Otsuka M	Striatal 18F-Dopa uptake and brain glucose metabolism by PET in patients with syndrome of progressive ataxia	J Neurol Sci (BIOA1994974 07531)			
P1		Pascual J	Neurochemistry of Parkinson's disease and parkinsonism plus	Rev Neurol	1997	25 Suppl 2	S141-6
P2	[ICP 29]	Pate BD	The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18-L-6-fluorodopa tracer in non-human primates	J Nucl Med	1991	32(6)	1246-51
P3		Pearce RK	Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia	Eur Neurol	1990	30 Suppl 1	9-14
P4		Peppard RF	Parkinsonism with neuroacanthocytosis	Can J Neurol Sci	1990	17(3)	298-301
P5		Peschanski M	Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon	Brain	1994	117 (Pt 3)	487-99
P6		Petruck KC	Treatment of refractory Parkinson's disease with adrenal medullary autografts utilizing two-stage surgery	Prog Brain Res	1990	82	671-6
P7	17	Piccini P	Etiology of Parkinson's disease: contributions from 18F-DOPA positron emission tomography	Adv Neurol	1999	80	227-31
P8		Piccini P	Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa	Ann Neurol	1997	41(2)	222-9

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			positron emission tomography study				
P9		Piccini P	Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias	Ann Neurol	1997	42(5)	720-6
P10	28	Piccini P	PET studies of the striatal dopaminergic system in Parkinson's disease (PD)	J Neural Transm Suppl	1995	45	123-31
P11		Pietrzik U	An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies	J Nucl Med	1994	35(12)	2011-8
P12		Price JC	Measurement of benzodiazepine receptor number and affinity in humans using tracer kinetic modeling, positron emission tomography, and carbon-11 flumazenil	J Cereb Blood Flow Metab (BIOA1993960 68320)			
P13		Przeborski S	Brain glucose metabolism and dopamine D2 receptor analysis in a patient with hemiparkinsonism-hemiatrophy syndrome	Mov Disord	1993	8(3)	391-5
P14	(B25)	Przedborski S	Nigrostriatal dopaminergic function in familiar amyotrophic lateral sclerosis patients with and without copper/zinc superoxide dismutase mutations	Neurology	1996	47(6)	1546-51
P15	(B24)	Przedborski S	Metabolic topography of the hemiparkinsonism-hemiatrophy syndrome	Neurology	1994	44(9)	1622-8
P16		Psylla M	Cerebral 6-[18F]fluoro-L-FDOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition	Brain Res	1997	767(1)	45-54
P17		Pycock CJ	Central dopaminergic receptor	J Neurol Sci	1977	31(1)	113-21

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			supersensitivity and its relevance to Parkinson's disease				
R1	59	Rajput AH	Is levodopa toxic to human substantia nigra?	Mov Disord	1997	12(5)	634-8
R2	43	Rajput AH	Accuracy of clinical diagnosis in Parkinsonism – A prospective study	Can J Neurol Sci	1991	18	275-8
R3	38	Rajput AH	Levodopa efficacy and pathological basis of parkinson syndrome	Clin Neuropharm	1990	13(6)	553-8
R4	18	Rakshi JS	Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]doap-PET study	Brain	1999	122(pt9)	1637-50
R5		Rakshi JS	Statistical parametric mapping of three dimensional 18F-dopa PET in early and advanced Parkinson's disease	Mov Disord	1996	11 (Sup 1)	147
R6		Reddy GN	Quality assurance and quality control methods for animal and human applications of no-carrier-added 6-[18F]fluorodopa for PET investigations of dopaminergic systems	Appl Radiat Isot	1993	44(7)	993-8
R7		Reith J	Blood-brain transfer and metabolism of 6-[18F]fluoro-L-dopa in rat	J Cereb Blood Flow Metab	1990	10(5)	707-19
R8		Remy P	Relationships between (18F)-fluorodopa uptake in the caudate nucleus and cognitive function in advanced Parkinson's disease	Soc Neurosci Abs	1998	24(1-2)	1221
R9		Remy P	Peduncular 'rubral' tremor and dopaminergic denervation: a PET study	Neurology	1995	45 (3 Pt 1)	472-7
R10		Remy P	Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients	Ann Neurol	1995	38(4)	580-8
R11		Remy P	Striatal dopaminergic denervation in pallidopyramidal disease demonstrated by	Ann Neurol	1995	38(6)	954-6

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			positron emission tomography				
R12		Rinne JO	Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivePontocerebellar atrophy variant of multiple system atrophy	Ann Neurol	1995	37(5)	568-73
R13		Rinne JO	PET examination of the monoamine transporter with [11C]beta-CIT and [11C]beta-CFT in early Parkinson's disease	Synapse	1995	21(2)	97-103
R14		Rinne JO	Decrease in human striatal dopamine D2 receptor density with age: a PET study with [11C]raclopride	J Cereb Blood Flow Metab	1993	13(2)	310-4
R15		Rinne JO	PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease	Mov Disord	1993	8(2)	134-8
R16		Rinne JO	Nigral degeneration in Parkinson's disease in relation to clinical features	Acta Neurol Scand Suppl	1991	136	87-90
R17		Rinne JO	PET demonstrates different behavior of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease	J Neurosci Res	1990	27(4)	494-99
R18		Rinne UK	Positron emission tomography demonstrated dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease	Mov Disord	1990	5(1)	55-9
R19		Rose S	Fluctuations in response to L-dopa in Parkinson's disease may be explained by changes in striatal dopamine turnover	Br J Pharmacol	1989	98 Suppl	816P
R20		Rosenow F	Neurological sequelae of cyanide intoxication: The patterns of clinical,	Ann Neurol (BIOA1996986			

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			magnetic resonance imaging, and positron emission tomography findings	02114)			
R21		Rossor MN	Progressive frontal gait disturbance with atypical Alzheimer's disease and corticobasal degeneration	J Neurol Neurosurg Psychiatry	1999	67(3)	345-52
R22		Rougemont D	Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease	J Neurol Neurosurg Psychiatry	1984	47(8)	824-30
R23		Rousset O	3D simulations of radiotracer uptake in deep nuclei of human brain	Comput Med Imaging Braph	1993	17(4-5)	373-9
R24		Rudnicki SA	Nervous system dysfunction in Waldenstrom's macroglobulinemia: response treatment	Neurology	1998	51(4)	1210-3
R25		Ruottinen H	Effects of MSO-B inhibition and peripheral COMT inhibition on fluorodopa PET in Parkinson's disease	Eur J Neurol	1995	2	161-
R26	(B29)	Ruottinen HM	Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction	Synapse	1997	27(4)	336-46
R27		Ruottinen HM	[18F]fluorodopa PET shows striatal dopaminergic dysfunction in juvenile normal ceroid lipofuscinosis	J Neurol Neurosurg Psychiatry	1997	6296)	622-5
R28	36	Ruottinen HM	Striatal [18F] fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease	J Neural Transm Park Dis Dement Sect	1995	10(2-3)	91-106

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
S1		Saha GB	Radiopharmaceuticals for brain imaging	Semin Nucl Med	1994	44(9)	1622-8
S2	8 [ICP 31]	Sawle GV	Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data	Arch Neurol	1994	51(3)	237-43
S3		Sawle GV	The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism implications for levodopa therapy of Parkinson's disease	Neurology	1994	44(7)	1292-7
S4		Sawle GV	Dopa-responsive dystonia	Ann Neurol	1994	36(5)	765-70
S5		Sawle GV	Asymmetrical pre-synaptic and post-synaptic changes in the striatal dopamine projection in dopa naive parkinsonism. Diagnostic implications the D2 receptor status	Brain	1993	116 (Pt 6)	853-67
S6		Sawle GV	[18F]-6-L-fluorodopa PET studies of graft and host dopaminergic function following fetal mesencephalic transplantation	Adv Neurol	1993	60	715-20
S7	10	Sawle GV	The detection of preclinical Parkinson's disease: what is the role of positron emission tomography	Mov Disord	1993	893)	271-7
S8		Sawle GV	Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants	Ann Neurol	1992	31(2)	166-73
S9		Sawle GV	The rate of progression of Parkinson's disease	Ann Neurol	1992	31(2)	229
S10		Sawle GV	The identification of presymptomatic	Ann Neurol	1992	32(5)	609-17

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			parkinsonism: clinical and [18F]dopa positron emission tomography studies in an Irish kindred				
S11	[S11]	Sawle GV	Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography	Brain	1991	114 (Pt 1B)	541-56
S12		Sawle GV	Obsessional slowness functional studies with positron emission tomography	Brain	1991	114(5)	2191-2202
S13	[ICP 30]	Sawle GV	Striatal function in normal aging: implications for Parkinson's disease	Ann Neurol	1990	28(6)	799-804
S14	No # given	Scatton B	Dopamine deficiency in the cerebral cortex in Parkinson disease	Neurology	1982	32(9)	1039-40
S15		Schneider JS	Differential recovery of volitional motor function, lateralized cognitive function, dopamine agonist-induced rotation and dopaminergic parameters in monkeys made hemi-parkinsonian by intracarotid MPTP infusion	Brain Res (BIOA1995981 80310)			
S16		Schwarz J	Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy?	Psychiatry Res	1998	83(1)	23-8
S17		Seeman P	Dopamine receptors and transporters in Parkinson's disease and schizophrenia	FASEB J	1990	4(10)	2737-44
S18		Shinotoh H	Fluorodopa and raclopride PET analysis of patients with Machado-Joseph disease	Neurology	1997	49(4)	1133-6
S19		Shinotoh H	Presynaptic and postsynaptic striatal	Neurology	1997	48(4)	1053-56

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			dopaminergic function in patients with manganese intoxication: A positron emission tomography study				
S20		Shinotoh H	[Neurotransmitter systems in the human brain studied by positron emission tomography].	Rinsho Shinkeigaku	1996	36(12)	1313-5
S21	[S21]	Shinotoh H	The use of PET in Parkinson's disease	Brain Cogn	1995	28(3)	297-310
S22		Shinotoh H	Dopamine D1 and D2 receptors in Parkinson's disease and striatonigral degeneration determined by PET	Adv Neurol	1993	60	488-93
S23		Shoulson J	Where do we stand on neuroprotection? Where do we go from here?	Mov Disord	1998	13 Supl 1	46-8
S24	68	Shulman LM	Levodopa toxicity in Parkinson disease: reality or myth?	Arch Neurol	2000	57	406-7
S25		Silber E	Hemiparkinsonism-hemiatrophy: A fluorodopa SPET study and beneficial response to medial pallidotomy	Neurology	1999	52 (6 Suppl 2)	A406-7
S26		Sjoholm H	Nigro-striatal degeneration demonstrated in parkinsonian patients with iodine-123-beta CIT SPECT: methods of quantitation	Acta Neurol Scand	1997	96(2)	91-6
S27		Smith GS	Serotonergic modulation of dopamine measured with [11c]raclopride and PET in normal human subjects	Am j Psychiatry	1997	154(4)	490-6
S28	[S28]	Snow BJ	Fluorodopa PET scanning in Parkinson's disease	Adv Neurol	1996	69	449-57
S29		Snow BJ	An aging effect in striatal fluorodopa uptake? Large versus small ROIs	J Cereb Blood Flow Metab	1994	14(5)	882-3
S30		Snow BJ	Positron emission tomographic studies of	Ann Neurol	1993	34(5)	733-8

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			dopa-responsive dystonia and early-onset idiopathic parkinsonism				
S31	[ICP 32]	Snow BJ	Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels	Ann Neurol	1993	34(3)	324-30
S32	[S32]	Snow BJ	Positron emission tomography in Parkinson's disease	Can J Neurol Sci	1992	19 (1 Suppl)	138-41
S33		Snow BJ	The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography	J Neurol Neurosurg Psychiatry	1991	54(1)	12-7
S34		Snow BJ	Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. The amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam	Arch Neurol	1990	47(8)	870-4
S35	[S35]	Sossi V	Basal ganglia studies with 3D acquisition and 2D reconstruction on a retractable septa PET scanner	J Comput Assisted Tomogr	1994	18(6)	1004-9
S36		Sossi V	Recovery of the human striatal signal in a slice oriented positron emission tomograph	J Nucl Med	1993	34(3)	481-7
S37		Spencer DD	Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease	N Engl J Med	1992	327(22)	1541-8
S38		Spencer SE	Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation	Neurology	1984	34(8)	1105-8
S39		Stern Y	Cognitive change following MPTP exposure	Neurology	1990	40(2)	261-4
S40		Stocklin GL	Is there a future for clinical fluorine-18	Eur J Nucl Med	1998	25(12)	1612-6

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			radiopharmaceuticals (excluding FDG)?				
S41	(B31)	Stout DB	Effects of large neutral amino acid concentrations on 6-[F-18]Fluoro-L-DOPA kinetics	J Cereb Blood Flow Metab	1998	18(1)	43-51
S42		Subramanian	Polymer-encapsulated PC-12 cells demonstrate high-affinity uptake of dopamine in vitro and 18F-Dopa uptake and metabolism after intracerebral implantation in nonhuman primates	Cell Transplant	1997	6(5)	469-77
T1		Takahashi H	Biochemical and fluorodopa positron emission tomographic findings in an asymptomatic carrier of the gene for dopa-responsive dystonia.	Ann Neurol	1994	35(3)	354-6
T3	4	Takahashi H	Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning	Lancet	1993	342 (8878)	1016-8
T2		Takahashi H	Clinical heterogeneity of dopa-responsive dystonia: PET observations	Adv Neurol	1993	60	586-90
T4	(C1)	Takikawa S	Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations	J Nucl Med	1994	35(6)	955-63
T5		Taniwaki T	Positron emission tomography (PET) in Machado-Joseph disease	J Neurol Sci	1997	145(1)	63-7
T6		Taniwaki T	Positron emission tomography (PET) in 'pure akinesia'	J Neurol Sci	1992	107(1)	34-9
T7		Tanji H	PET study of striatal fluorodopa uptake and dopamine D2 receptor binding in a patient with juvenile parkinsonism	Eur J Neurol (BIOA1998003 22192)			

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
T8		Tedroff J	Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity	Synapse	1998	28(4)	280-7
T9		Tedroff J	L-DOPA modulates striatal dopaminergic function in vivo: evidence from PET investigations in nonhuman primates	Synapse	1997	25(1)	56-61
T10		Tedroff J	Functional positron emission tomographic studies of striatal dopaminergic activity. Changes induced by drugs and nigrostriatal degeneration	Adv Neurol	1996	69	443-8
T11		Tedroff J	Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.	Neurology	1996	4695)	1430-6
T12		Tedroff J	Cerebral uptake and utilization of therapeutic [β -11C]-L-DOPA in Parkinson's disease measured by positron emission tomography.	Acta Neurol Scand	1992	85(2)	95-102
T13		Tedroff J	Estimation of regional cerebral utilization of [1C]-L-3,4-dihydroxy-phenylalanine (DOPA) in the primate by positron emission tomography	Acta Neurol Scand	1992	85(3)	166-73
T14		Tedroff J	Central action of benserazide after COMT inhibition demonstrated in vivo by PET	J Neural Transm Gen Sect	1991	85(1)	11-7
T15		Tedroff J	Striatal kinetics of [11C]-(+)-nomifensine and 6-[18F]fluoro-L-dopa in Parkinson's disease	Acta Neurol Scan	1990	81(1)	24-30

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			measured with positron emission tomograph				
T16		Tedroff J	Monoamine re-uptake sites in the human evaluated in vivo by means of 11C-nomifesine and positron emission tomography: the effects of age and Parkinson's disease	Acta Neurol Scand	1988	77(3)	192-201
T17		Tetrud JW	Parkinsonism caused by petroleum waste ingestion	Neurology (BIOA1994974 07239)			
T18		Tewson TJ	PET radiopharmaceuticals: State-of-the-art and future prospects	Semin Nucl Med	1998	28(3)	221-34
T19		Tiihonen J	Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography	Mol Psychiatry	1998	3(2)	156-61
T20	(C3)	Tissingh G	Nigrostriatal dopaminergic with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET	J Nucl Med	1997	38(8)	1271-2
T21		Tissingh G	[123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls	Eur J Nucl Med	1997	24(9)	1171-4
T22		Torstenson R	Effect of apomorphine infusion on dopamine synthesis rate relates to dopaminergic tone	Neuropharmacology	1998	37(8)	989-95
T23	6	Trebosse R	Validation of the three-dimensional acquisition mode in positron emission tomography for the quantitation of [18F]fluoro-DOPA uptake in the human striata	J Cereb Blood Flow Metab	1998	18(9)	951-9

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
T24	26 (C4)	Trenkwalder C	Positron emission tomographic studies in restless legs syndrome	Mov Disord	1999	14(1)	141-5
T25		Turjanski N	Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies	Neurology	1999	52(5)	932-7
T26		Turjanski N	Dopaminergic function in patients with posttraumatic parkinsonism: an 18F-dopa PET study	Neurology	1997	49(1)	183-9
T27		Turjanski n	In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinésias	Neurology	1997	49(3)	717-23
T28		Turjanski N	PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome	J Neurol Neurosurg Psychiatry	1994	57(6)	688-92
T29		Turjanski N	Comparison of striatal 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson's disease, and dopa-responsive dystonia	Neurology	1993	43(8)	1563-8
U1		Uitti RJ	Parkinsonism induced by solvent abuse	Ann Neurol	1994	35(5)	616-9
V1		Vallabhajosula S	PET studies in psychiatry: Validity, accuracy and future	J Nucl Med	1994	35(1)	24-6
V2	5	Vidailhet M	Dopaminergic dysfunction in midbrain dystonia: anatomoclinical study using 3-dimensional magnetic resonance imaging and fluorodopa F 18 positron emission tomography	Arch Neurol	1999	56(8)	982-9
V3		Vingerhoets FJ	Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?	Ann Neurol	1997	41(1)	58-64

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
V4	[V4]	Vingerhoets FJ	Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-Dopa PET in Parkinson's disease	J Nucl Med	1996	37(3)	421-6
V5		Vingerhoets FJ	Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects	J Nucl Med	1994	35(1)	18-24
V6	[ICP 34]	Vingerhoets FJ	Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism	Ann Neurol	1994	36(5)	759-64
V7		Vingerhoets FJ	Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions	Ann Neurol	1994	36(5)	765-70
V8	[ICP 35]	Volkow ND	PET evaluation of the dopamine system of the human brain	J Nucl Med	1996	37(7)	1242-56
W1		Wahl L	Quantification of dopamine metabolism in man: a mathematically justifiable approach	Phys Med Biol	1996	41(6)	963-78
W2		Wahl L	Modeling of fluorine-18-6-fluoro-L-Dopa in humans	J Nucl Med	1996	37(3)	432-7
W3	32	Wahl LM	Statistical power analysis for PET studies in humans	J Nucl Med	1998	39(10)	1826-9
W4		Wang RF	Determination of unchanged [18F]dopamine in human and non-human primate plasma during positron emission tomography studies: a new solid-phase extraction method comparable to radio-thin-layer chromatography analysis	J Chromatogr B Biomed Sci App	1997	693(2)	265-70
W5		Waters CH	Phenotypic expression of X-linked dystonia-parkinsonism (lubag) in two women	Neurology	1993	43(8)	1555-8
W6		Wayne MWR	Assessment of fetal tissue transplantation in	Neurology	1994	44(10)	1777-80

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			Parkinson's disease: Does PET play a role?				
W7		Weder BJ	Impaired somatosensory discrimination of shape	Hum Brain Mapp	1999	8(1)	1-12
W8	69	Weiner WJ	Is levodopa toxic?	Arch Neurol	2000	57	408-9
W9		Wenning GK	Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease	Ann Neurol	1997	42(1)	95-107
W10		Westerman K	Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers	Mov Disord	1995	10(5)	596-603
W11		Widner H	Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	N Engl J Med	1992	327(22)	1556-63
W12		Wolters EC	Dopamine agonists in Parkinson's disease	Neurology	1995	45 3 suppl3	S28-34
W13	68	Wszolek ZK	Western Nebraska family (family D) with autosomal dominant parkinsonism	Neurology	1995	45(3)	502-5
W14		Wu JC	Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal	Neuropsychopharmacology	1997	17(6)	402-9
W15	(C7)	Wu JC	Increased dopamine activity associated with stuttering	Neuroreport	1997	8(3)	767-70
Y1	31	Yahr MD	Parkinson's disease: new approaches to diagnosis and treatment	Acta Neurol Scand Suppl	1993	146	22-5
Y2		Yahr MD	Parkinson's disease. The L-dopa era.	Adv Neurol	1993	60	11-7
Y3		Yee RE	Nigrostriatal reduction of aromatic L-amino acid decarboxylase activity in MPTP-treated squirrel monkeys: in-vivo and in-vitro	J Neurochem	1999	Revised manuscript	1-39

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			investigations			W99-67	
Y4	[ICP 37]	Yee RE	Novel observations with FDOPA-PET imaging after early nigrostriatal damage	Ann Neurol	(submitted 1999)		1-39
Y5		Yost Y	Synthesis and preliminary evaluation of (s)-(2-[18F]fluoro-4,5-dihydroxyphenyl)-2-methyl L-alanine, (S)-[18F]-FMEDOPA, a potentially improved imaging agent for the presynaptic dopaminergic nervous system	Nucl Med Biol	1996	23(7)	857-65
Y6	(C10)	Yu DC	The assessment of the non-equilibrium effect in the 'patlak analysis' of Fdopa PET studies	Phys Med Biol	1995	40(7)	1243-54
Y7	(C9)	Yu DC	Methods for improving quantitation of putamen uptake constant of FDOPA in PET studies	J Nucl Med	1993	34(4)	679-88
Z1		Zigmond MJ	Partial damage to nigrostriatal bundle: compensatory changes and the action of L-dopa	J Neural Transm Suppl	1990	29	217-32
1	<PT>	Albanese A	Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: Behavioral, morphological and biochemical correlates.	Neuroscience	1993	55	823-32
2	<PK>	Begg CB	Assessment of diagnostic tests when disease verification is subject to selection bias	Biometrics	1983	39	207-15
3	<PK>	Bhargava HK	Beyond spreadsheets: tools for building decision support systems	Computer	1999	32	31-9
4	<PT>	Burns RS	A primate model of Parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.	Proc Natl Acad Sci	1983	80	4546-50
5	<PT>	Cantacuzene D	Effect of fluorine substitution on the agonist	Science	1979	204	1217-9

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			specificity of norepinephrine				
6	<PK>	Cedarbaum JM	Effect of supplemental carbidopa on bioavailability of L-dopa	Clin Neuropharmacol	1986	9(2)	153-9
7	<PK>	Collins JM	Positron emission tomography for selection and assessment of therapy				
8	<PT>	Cumming P	The metabolism of [18F]6-fluoro-L-3,4-dihydroxyphenylalanine in the hooded rat	J Neurochem	1987	48	601-8
9	<PK>	Devous MD	SPECT brain imaging in epilepsy: a meta-analysis	J Nucl Med	1998	39	285-93
10	<PK>	Firnau G	Metabolites of 6-[18F]fluoro-L-dopa in human blood	J Nucl Med	1988	29(3)	363-9
11	<PT>	Firnau G	Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate	J Neurochem	1987	48	1077-82
12	<PT>	Garnett ES	Dopamine visualized in the basal ganglia of living man	Nature	1983	305	137-8
13	<PT>	Garnett S	Striatal dopamine metabolism in living monkeys examined by positron emission tomography	Brain Res	1983	280	169-71
14	<PK>	Hammerstad JP	The transport of L-6-fluorodopa and its metabolites from the blood to cerebrospinal fluid and brain	Ann Neurol	1993	34(4)	603-8
15	<PK>	Hartvig P	Regional brain kinetics of 6-fluoro-(beta-11C)-L-dopa and (beta-11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography	J Neural Transm Gen Sect	1992	87(1)	15-22
16	<PT>	Hoffman JM	The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography	J Nucl Med	1992	33	1472-77
17	<PK>	Irwig L	Meta-analytic methods for diagnostic test accuracy	J Clin Epidemiol	1995	48	119-32
18	<PK>	Jeffrey RF	The effect of carbidopa and indomethacin on the	Br J Clin	1988	25(2)	195-201

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			renal response to gamma-L-glutamyl-L-dopa in normal man	Pharmacol			
19	<PK>	Kaplan RM	A general health policy model: update and applications	Health Serv Res	1988	23	203-35
20	<PK>	L'abbe KA	Meta-analysis in clinical research	Ann Intern Med	1987	107	224-33
21	<PT>	Langston JW	The next frontier in Parkinson's disease: Presymptomatic detection	Neurology	1991	41 (suppl 2)	5-7
22	<PT>	Langston JW	Chronic parkinsonism in humans due to a product of meperidine-analog synthesis	Science	1983	219	979-80
23	<PK>	Laruelle M	Imaging dopamine transmission in schizophrenia: a review and meta-analysis	Q J Nucl Med	1998	42	211-21
24	<PT>	Leenders KL	Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography	Ann Neurol	1986	20	258-62
25	<PK>	Leppert PS	The effects of carbidopa dose and time and route of administration on systemic L-dopa levels in rats	Pharm Res	1988	5(9)	587-91
26	<PT>	LeWitt PA	Markers of dopamine metabolism in Parkinson's disease	Neurology	1992	42	2111-17
27	<PK>	Littenberg B	Technetium bone scanning in the diagnosis of osteomyelitis: a meta-analysis of test performance. Diagnostic Technology Assessment Consortium	J Gen Intern Med	1992	7	158-64
28	<PT>	Lloyd KG	Occurrence and distribution of aromatic L-amino acid (L-DOPA) decarboxylase in the human brain	J Neurochem	1972	19	959-67
29	<PT>	Luxen A	Production of 6-[18F]fluoro-L-dopa and its metabolism in vivo-a critical review	Nucl Med Biol	1992	19	149-58
30	<PK>	Lyytinen J	Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease	Mov Disord	1997	12(4)	497-505
31	<PK>	Maguire RP	Variance in parametric images: direct estimation	Phys Med Biol	2000	45(1)	91-102

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			from parametric projections				
32	<PK>	Maguire RP	An investigation of multiple time/graphical analysis applied to projection data: theory and validation	J Comput Assist Tomogr	1997	21(2)	327-31
33	<PT>	Martin WRW	Nigrostriatal function in humans studied with PET	Ann Neurol	1989	26	535-42
34	<PK>	Missimer J	On two methods of statistical image analysis	Hum Brain Mapp	1999	8(4)	245-58
35	<PK>	Moses LE	Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations	Stat Med	1993	12	1293-1316
36	<PK>	Mozley PD	Dosimetry of a D2/D3 dopamine receptor antagonist that can be used with PET or SPECT	J Nucl Med	1995	36(7)	1322-31
37	<PT>	Pate B	Correlation of striatal fluorodopa uptake in the MPTP monkeys with dopaminergic indices.	Ann Neurol	1993	34	331-8
38	<PK>	Pestana M	Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease	Kidney Blood Press Res	1998	21(1)	59-65
39	<PK>	Rose S	Peripheral pharmacokinetic handling and metabolism of L-dopa in the rat: the effect of route of administration and carbidopa pretreatment	J Pharm Pharmacol	1991	43(5)	325-30
40	<PT>	Sawle GV	Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants	Ann Neurol	1992	31(2)	166-73
41	<PK>	Thacker SB	Meta-analysis. A quantitative approach to research integration	JAMA	1988	259	1685-89
42	<PT>	Torsten R	A comparison of 11C-labeled L-dopa and L-fluorodopa as PET tracers for presynaptic dopaminergic system	J Cereb Blood Flow Metab	1999	19	1142-9
43	<PK>	Torstenson R	A comparison of 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography	J Cereb Blood Flow Metab	1999	19(10)	1142-9

PET: F-DOPA LITERATURES [MASTER INDEX]

Tab #	Origin	Primary Author	Title	Journal	Year Published	Volume	Pages
			tracers for the presynaptic dopaminergic system				
44	<PK>	Wahl L	The distribution and kinetics of [18F]6-fluoro-3-O-methyl-L-dopa in the human brain	J Cereb Blood Flow Metab	1994	14(4)	664-70
Book		Goodman and Gillman	Pharmacopeia		1996	9 th edition	
Book		Samuel/Feske	Office Practice of Neurology		1996		
Book		Cooper	Biochemical Basis of Neuropharmacology		1996	7 th edition	
Book		McGraw Hill	Neurology Principle and Practice		1997		
Book			Physician's Desk Reference		1999	53 rd edition	
Book		Jankovic/ Tolosa	Parkinson's disease and movement disorder			3 RD edition	991-1016
Book		Murray	Nuclear Medicine in clinical Diagnosis and Treatment		1994	Volume 1	589-643
Book		Harbert	Nuclear Medicine: Diagnosis and Therapy		1996		375-85
Review			The Safety and Efficacy of COMT Inhibitors (sumposium at XIII International Congress on Parkinson's Disease, Vancouver, Canada)		2000	Supplement (April)	